TrialInvestigational new drugs2024

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.

Elisabeth I Heath et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.